Verona Pharma PLC American Depositary Share (VRNA) Earns News Sentiment Score of 0.11
News headlines about Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) have been trending somewhat positive on Thursday, Accern Sentiment reports. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Verona Pharma PLC American Depositary Share earned a news sentiment score of 0.11 on Accern’s scale. Accern also assigned media coverage about the company an impact score of 45.5500237999941 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
Shares of Verona Pharma PLC American Depositary Share (NASDAQ:VRNA) traded up $0.24 during mid-day trading on Thursday, reaching $11.75. 200 shares of the company’s stock traded hands, compared to its average volume of 5,573. Verona Pharma PLC American Depositary Share has a one year low of $10.44 and a one year high of $17.50.
Several research analysts have weighed in on VRNA shares. Zacks Investment Research raised shares of Verona Pharma PLC American Depositary Share from a “sell” rating to a “hold” rating in a research note on Thursday, August 17th. Wedbush reaffirmed an “outperform” rating and set a $33.00 target price on shares of Verona Pharma PLC American Depositary Share in a research note on Friday, September 8th. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus target price of $24.20.
Verona Pharma plc, a clinical stage biopharmaceutical company, researches, discovers, and develops therapeutic drugs to treat respiratory diseases primarily in the United Kingdom and North America. The companys lead product is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which is in Phase IIa clinical trial that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease, cystic fibrosis, and asthma.
Receive News & Ratings for Verona Pharma PLC American Depositary Share Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma PLC American Depositary Share and related companies with MarketBeat.com's FREE daily email newsletter.